<DOC>
	<DOCNO>NCT02797340</DOCNO>
	<brief_summary>The study evaluate pharmacokinetics metformin heart failure patient acute chronic state relation metformin transporter genotype . Participants heart failure type 2 diabetes treat metformin . Hypothesis : Primary : The renal clearance metformin decrease acute state congestive heart failure compare chronic state . Secondary : Metformin trough value HF patient influence polymorphisms transporter gene relevant pharmacokinetics metformin .</brief_summary>
	<brief_title>Metformin Pharmacokinetics Patients With Chronic Acute Heart Failure</brief_title>
	<detailed_description>Background : Heart failure ( HF ) common disease diabetes/insulin resistance present approximately 50 % HF patient . Metformin commonly prescribe oral anti-diabetic drug , huge inter-individual variability trough steady-state metformin concentration type 2 diabetic demonstrate . Genetic polymorphism metformin transporter gene likely direct impact metformin pharmacokinetics variability drug response , influence polymorphism transporter gene circulate metformin level presently unknown HF patient . Objectives : A ) To compare pharmacokinetics metformin 12 diabetic patient HF acute chronic state . B ) To investigate influence polymorphism gene encode metformin transporter proteins metformin trough level 150 diabetic HF patient . Design : An open , single-center study enrol 12 patient acute heart failure ( study A ) 150 patient stable chronic heart failure ( study B ) . The participant diabetes already treat metformin prior inclusion . Through repeat blood draw , concentration metformin determine along genotyping metformin transporter gene . Primary outcome : Study A : Changes renal clearance metformin patient acute chronic heart failure . Study B : Mean trough steady-state concentration metformin emphasis intra-interindividual variability HF patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients heart failure LVEF &lt; 45 % within 12 month prior inclusion NYHAclass I , II , III IV Ability understand write patient information give inform consent Diabetes Type 2 ( metformin treatment &gt; 1 month ) Stable dosage metformin treatment least 1 week prior examination Age &lt; 18 year Current abuse alcohol drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>